The trial tested whether glucosamine and chondroitin used separately or in combination, and in comparison to placebo and celecoxib, are effective in reducing pain and improving functional ability
Central arterial blood pressure is the pressure in the aorta, which determines the stress and damage on the heart and central vessels. Lower central arterial blood pressure readings
The trials will test the synergistic effect of the combination therapy in the treatment of patients with advanced myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). HDAC inhibitors,
The extension data, presented for at the American Society of Nephrology 38th annual meeting, mirror earlier results in dialysis patients, suggesting that CERA provides consistent anti-anemia activity in
The extension study enrolled 93 patients, of which 32 were treated with Fosrenol for up to six years. The study revealed that as patients continued with the therapy,
In October, Abbott submitted applications to the FDA and the European Medicines Agency seeking approval to market Humira as a treatment for ankylosing spondylitis (AS). The drug is
Amgen now expects to file new data with the FDA on extended dosing regimens for Aranesp in chronic kidney disease (CKD) by the end of 2005. In the
The researchers hope to find a way of genetically characterizing patients to predict responsiveness to treatment, and help physicians to determine the best treatment option for their patients.
Morphotek will apply its proprietary Human Morphodoma antibody technology to develop novel antibodies for use in the treatment of advanced melanoma, lung cancer and other solid malignancies that
The study of 58 patients found that RenaMed’s therapy increased survival rate by 72% at 28 days, a trend for improved survival sustained through 90 and 180 days.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.